Kunkel Lori Anne — SEC Form 4 filings
SEC reporting owner CIK 1536368. 16 Form 4 filings on record with FilingPulse; latest filed 2026-07-08.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-04-10 to 2026-07-08. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 5 legs across 2 filings — 20,000 shares, $850,255 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 21.
- Largest priced transaction: sale of 5,889 shares @ $50.84 ($299,421) in Enliven Therapeutics, Inc., filed 2026-07-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | Director | 6 | — | 5 legs · 20,000 sh · $850,255 | 5 |
| Oric Pharmaceuticals, Inc. (ORIC) | Director | 7 | — | — | 13 |
| Nurix Therapeutics, Inc. (NRIX) | Director | 3 | — | — | 3 |
Form 4 filings — Kunkel Lori Anne
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-08 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 4,111 @ $49.98 · Sale (S): 5,889 @ $50.84 | EDGAR |
| 2026-06-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Sale (S): 7,779 @ $34.28 · Sale (S): 1,867 @ $35.36 · Sale (S): 354 @ $35.82 | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 17,126 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 15,958 @ $1.12 · Option exercise (M): 15,958 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 10,000 @ $7.90 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 5,534 @ $3.75 · Option exercise (M): 5,534 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 27,666 @ $3.75 · Option exercise (M): 20,500 @ $6.33 · Option exercise (M): 27,666 (derivative) @ $0 · Option exercise (M): 20,500 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 15,368 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2024-07-18 | 4 | Nurix Therapeutics, Inc. (NRIX) | Gift (G): 54,027 @ $0 | EDGAR |
| 2024-06-14 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Grant/award (A): 25,600 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Oric Pharmaceuticals, Inc. (ORIC) | Option exercise (M): 20,500 @ $3.75 · Option exercise (M): 20,500 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Nurix Therapeutics, Inc. (NRIX) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-04-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 37,882 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1536368 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →